To take advantage of the growing knowledge of cellular signaling pathways, modern-day drug discovery faces an increasing challenge to develop assays to screen for compounds that modulate protein-protein interactions. One bottleneck in achieving this goal is a lack of suitable and robust assay technologies amenable to a high-throughput format. In this report, we describe how we utilized Alphascreen™ technology to develop a high-throughput assay to monitor ligand binding to a member of the tumor necrosis factor receptor superfamily. We expressed a fusion protein consisting of the extracellular domain of the OX40 receptor with the constant domains of human IgG. In the presence of OX40 ligand, we determined a binding affinity constant consistent with reported values and optimized the protocol to develop a simple, homogeneous, and sensitive binding assay in a 384-well format. Finally, we assessed if this system could identify small peptides capable of inhibiting the OX40 receptor and ligand interaction. The results showed that the assay was able to detect such peptides and could be used to launch a high-throughput screening campaign for small molecules able to prevent OX40 receptor activation. (Journal of Biomolecular Screening 2003:522-532)
2. Toogood PL: Inhibition of protein-protein association by small molecules: approaches and progress . J Med Chem2002;45: 1543-1558 .
3.
3. Ockey DA, Gadek TR: Inhibitors of protein-protein interactions . Expert Opin Ther Patents2002;12: 393-400 .
4.
4. Cubitt AB, Heim R, Adams SR, Boyd AE, Gross LA, Tsien RY: Understanding, improving and using green fluorescent proteins . Trends Biochem Sci1995;20: 448-455 .
5.
5. Xu Y, Piston DW, Johnson CH: A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins . Proc Natl Acad Sci U S A1999;96: 151-156 .
6.
6. Förster T: Zwischenmolekulare Energiewanderung und Fluoreszenz . Ann Phys1948;2: 54-75 .
7.
7. Ullman EF, Kirakossian H, Singh S, et al: Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence . Proc Nat Acad Sci U S A1994;91: 5426-5430 .
9. Patterson DJ, Jefferies WA, Green JR, et al: Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts . Mol Immunol1987;24: 1281-1290 .
10.
10. Stuber E, Neurath M, Calderhead D, Fell HP, Strober W: Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells . Immunity1995;2: 507-521 .
11.
11. Imura A, Hori T, Imada K, et al: The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells . J Exp Med1996;183: 2185-2195 .
12.
12. Weinberg AD, Lemon M, Jones AJ, et al: OX-40 antibody enhances for autoantigen specific Vβ8.2 T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis . J Neurosci Res1996;43: 42-49 .
13.
13. Brugnoni D, Bettinardi A, Malacarne F, Airo P, Cattaneo R: CD134/OX40 expression by synovial fluid CD4+ T lymphocytes in chronic synovitis . Br J Rheumatol1998;37: 584-585 .
14.
14. Matsumura Y, Imura A, Hori T, Uchiyama T, Imamura S: Localization of OX40/gp34 in inflammatory skin diseases: a clue to elucidate the interaction between activated T cells and endothelial cells in infiltration . Arch Dermatol Res1997;289: 653-656 .
15.
15. Tittle TV, Weinberg AD, Steinkeler CN, Maziarz RT: Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease . Blood1997;89: 4652-4658 .
16.
16. Weinberg AD, Bourdette DN, Sullivan TJ, et al: Selective depletion of myelin-reactive T cells with the anti-OX40 antibody ameliorates autoimmune encephalomyelitis . Nat Med1996;2: 183-189 .
17.
17. Tsukada N, Akiba H, Kobata T, Aizawa Y, Yagita H, Okumura K: Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone-marrow transplantation . Blood2000;95: 2434-2439 .
18.
18. Yoshioka Y, Nakajima A, Akiba H, et al: Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis . Eur J Immunol2000;30: 2815-2823 .
19.
19. Higgins LM, McDonald SAC, Whittle N, Crockett N, Shields J, MacDonald TT: Regulation of T cell activity in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand fusion protein . J Immunol1999;162: 486-493 .
20.
20. Weinberg, AD, Wegmann KW, Funatake C, Whitham RH: Blocking OX40/OX40-L interaction in vitro and in vivo leads to decreased T-cell function and amelioration of experimental allergic encephalomyelitis . J Immunol1999;162: 1818-1826 .
21.
21. Taylor L, Bachler M, Duncan I, et al: In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions . J Leuk Biol2002;72: 522-529 .
22.
22. Al-Shamkhani A, Mallett S, Brown MH, James W, Barclay AN: Affinity and kinetics of the interaction between soluble trimeric OX40 ligand, a member of the tumor necrosis factor superfamily, and its receptor OX40 on activated T cells . J Biol Chem1997;272: 5275-5282 .
23.
23. Godfrey WR, Fagnoni FF, Harara MA, Buck D, Engleman EE: Identification of a human OX-40 ligand, a costimulator of CD T cells with homology to tumor necrosis factor . J ExpMed1994;180: 757-762 .
24.
24. Zhang JH, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays . J Biomol Screen1999;4: 67-73 .
25.
25. Cheng YC, Prusoff WH: Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I) of an enzymatic reaction . Biochem Pharmacol1973;22: 3099-3108 .
26.
26. Mancini F, Toro CM, Mabilia M, Giannangeli M, Pinza M, Milanese C: Inhibition of tumor necrosis factor-alpha (TNF-alpha)/TNF-alpha receptor binding by structural analogues of suramin . Biochem Pharmacol1999;58: 851-859 .
27.
27. Gray PW, Barrett K, Chantry D, Turner M, Feldmann M: Cloning of the human tumor necrosis factor (TNF) receptor cDNA and expression of soluble TNF-binding protein . Proc Natl Acad Sci U S A1990;87: 7380-7384 .
28.
28. Marsters SA, Frutkin AD, Simpson NJ, Fendly BM, Ashkenazi A: Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding . J Biol Chem1992;267: 5747-5750 .
29.
29. Owalabi JB, Rikalla G, Tehim A, et al: Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonists, in the rat . Proc Natl Acad Sci U S A1999;289: 1271-1276 .
30.
30. Baba M, Nishimura O, Kanzaki N, et al: A small-molecule nonpeptide CCR5 antagonist with highly potent and selective anti-HIV activity . Proc Natl Acad Sci U S A1999;96: 5698-5702 .
31.
31. Degterev A, Lugovsky A, Cardone M, et al: Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xl . Nature Cell Biol2001;3: 173-182 .
32.
32. Haggarty SJ, Mayer TU, Miyamoto DT, et al: Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb apoptosis . Chem Biol2000;7: 275-286 .
33.
33. Sharma SV, Oneyama C, Tamashita Y, et al: UCS15A, a non-kinase inhibitor of src signal transduction . Oncogene2001;20: 2068-2079 .
34.
34. Wu P, Brand L: Resonance energy transfer: methods and applications . Anal Biochem1994;218: 1-13 .
35.
35. Glickman JF, Wu X, Mercuri R, et al: A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors . J Biomol Screen2002;7: 3-10 .
36.
36. Heitz F, Wilson J, Fremaux C, Nichols A, Scheer A: Functional screening of GPCR's: the alpha screen approach . Paper presented at the 7th annual IBC meeting: G-protein coupled receptors: from ligand identification to drug targets, San Diego, CA, 2002.
37.
37. Boute N, Jockers R, Issad T: The use of resonance energy transfer in high-throughput screening: BRET versus FRET . Trends Pharmacol Sci2002;23: 351-354 .
38.
38. Eidne KA, Kroeger KM, Hanyaloglu AC: Applications of novel resonance energy transfer techniques to study dynamic hormone receptor interactions in living cells . Trends Endocrinol Metabol2002;13: 415-421 .
39.
39. Moore KJ, Turconi S, Miles-Williams A, et al: A homogeneous 384-well high throughput screen for novel tumor necrosis factor receptor: ligand interactions using time resolved energy transfer . J Biomol Screen1999;4: 205-214 .
